Circulating Tumor Cell Analysis: a new workflow combining ScreenCell Technology with Stilla Crystal Digital PCR®
Explore the collaboration between ScreenCell and Stilla Technologies, two innovative French platforms that offer a fluid comprehensive workflow for the enrichment and molecular analysis of circulating tumor cells.
Circulating tumor cells provide a valuable window into cancer progression, treatment response, and minimal residual disease. By combining ScreenCell’s enrichment technology with Stilla’s digital PCR platform, researchers and clinicians gain a streamlined approach to detecting and analyzing cancer mutations with high sensitivity and precision while using a small volume of samples.
Download Nio Digital PCR Brochure
About Stilla Technologies: A pioneer company in digital PCR (dPCR), Stilla provides high-precision molecular analysis solutions for applications in oncology, liquid biopsy, infectious disease research, and more. Their Crystal Digital PCR™ technology, powered by the Nio® Digital PCR system, enables absolute quantification of nucleic acids with exceptional sensitivity and reproducibility.
About ScreenCell: A French biotechnology company founded in 2010, ScreenCell specializes in liquid biopsy technology for isolating and analyzing circulating tumor cells (CTCs) from blood samples. Their innovative, non-invasive technology enables the capture of CTCs without the need for additional equipment, facilitating applications in cytology, molecular biology, and cell culture.